Christopher Fox, Ph.D.

Senior Vice President, Formulations

Dr. Christopher Fox leads the formulation platform development and optimization at AAHI, specifically development of GMP adjuvant formulations for clinical evaluation of vaccine candidates against a variety of infectious diseases. In his role, Dr. Fox directs formulation innovation including the development of thermostable, dry powder vaccine candidates and the incorporation of various adjuvant formulations in vaccine candidates to induce stronger and more robust immune responses than current vaccine technology. Since joining AAHI in 2007, he has served as Principal Investigator on multiple vaccine development contracts involving Phase 1 clinical trials evaluating pragmatic solutions to equitably accessible vaccines, such as temperature-stable vaccines and intranasally administered vaccines, ensuring vaccines can reach people in resource-limited areas. Dr. Fox also directs AAHI's efforts to transfer adjuvant formulation manufacturing know-how and processes around teh world and to train local manufacturing personnel to enable global self-reliance to protect against emerging threats. He has successfully executed technology transfer to manufacturing sites around the world, including Brazil, Eastern Europe, India, and South Africa. Dr. Fox works closely with AAHI's Product Development and Characterization, RNA Platform and GMP teams to anticipate challenges that hinder product manufacture and limit global accessibility and to provide custom formulation solutions to enhance functionality of drug products and improve point of care. 

Dr. Fox is a scientist with 20 years of experience in vaccine and drug formulation and characterization, including the major classes of clinical adjuvant formulations such as aluminum salts, oil-in-water emulsions, liposomes, and nanostructured lipid carriers for nucleic acid delivery. He received his BS in Biological Engineering from Utah State University and his PhD in Bioengineering from Unviersity of Utah, where he focused on analytical characterization efforts as a key scientist on multiple grants and contracts as well as supporting AAHI's partners for various vaccine indications including malaria, leishmaniasis, and influenza. He has authored over 130 publications including serving as editor for the Springer Methods in Molecular Biology volume entitled "Vaccine Adjuvants: Methods and Protocols" published in 2017. 

Education

Ph.D., Bioengineering, University of Utah, 2007

BS, Biological Engineering, Utah State University, 2003

Recent Grants and Contracts

Principal Investigator on NIH-funded project developing a thermostable adjuvant tuberculosis vaccine candidate (Contract No. HHSN272201400041C). 

Principal Investigator on NIH-funded project developing an intranasal adjuvanted amebiasis vaccine candidate (Contract No. HHSN272201800025C).

Principal Investigator on NIH-funded project engineering sustainable squalene analogues for novel vaccine adjuvant emulsions for sustainable, sufficient supply of vaccine raw materials (Grant No. 1R01AI135673-01AI).

Principal Investigator on BARDA-funded project establishing an adjuvant hub to enable adjuvanted influenza vaccines in under-resourced nations (Contract No. IDSEP140022).